Chugai Pharmaceutical (CHGCY) Stock Price, News & Analysis

Company Overview

Chugai Pharmaceutical Co., Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics. One of its best-known products is tocilizumab (marketed in many territories through collaborative arrangements), reflecting the company’s capabilities in immunology and antibody engineering. Chugai’s product portfolio and pipeline include both in-house assets and programs developed in collaboration with external partners, demonstrating a mix of internal R&D and strategic alliances to advance new medicines.

Chugai maintains a long-standing strategic partnership with the Roche Group and operates primarily in the Japanese market while leveraging global commercialization channels through alliances. The company supports clinical development and manufacturing activities in Japan and engages with international partners to expand the reach of its therapies. Chugai is managed by a professional leadership and scientific team with experience in pharmaceutical R&D and commercial operations, and it positions itself as a research-oriented company within the global biopharmaceutical landscape.

Key Stats

• Today's Range: $26.91 to $27.67
• 50-Day Range: $23.26 to $33.61
• 52-Week Range: $19.50 to $34.84
• Volume: 96,781 shs
• Average Volume: 240,701 shs
• Market Capitalization: $88.75 billion
• P/E Ratio: 29.96
• Dividend Yield: 2.30%
• Price Target: N/A
• Consensus Rating: Strong Buy

Chugai Pharmaceutical Stock Analysis - MarketRank™

Chugai Pharmaceutical scored higher than 10% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.2 / 5
• Analyst Rating: Strong Buy

Amount of Analyst Coverage

Chugai Pharmaceutical has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Chugai Pharmaceutical is 30.00, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.35.

Price to Earnings Ratio vs. Sector

The P/E ratio of Chugai Pharmaceutical is 30.00, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 29.20.

Price to Book Value per Share Ratio

Chugai Pharmaceutical has a P/B Ratio of 6.55. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for CHGCY.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Chugai Pharmaceutical pays a meaningful dividend of 2.35%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Chugai Pharmaceutical does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Chugai Pharmaceutical is 68.89%. This payout ratio is at a healthy, sustainable level, below 75%.

News and Social Media

• Score: 4.1 / 5
• News Sentiment: N/A

News Sentiment

Chugai Pharmaceutical has a news sentiment score of 1.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Chugai Pharmaceutical this week, compared to 0 articles on an average week.

MarketBeat Follows

3 people have added Chugai Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Chugai Pharmaceutical insiders have not sold or bought any company stock.

Percentage Held by Institutions

0.01% of the stock of Chugai Pharmaceutical is held by institutions.

CHGCY Stock Analysis - Frequently Asked Questions

How have CHGCY shares performed this year?

Chugai Pharmaceutical's stock was trading at $26.27 at the beginning of the year. Since then, CHGCY shares have increased by 2.8% and is now trading at $27.00.

How were Chugai Pharmaceutical's earnings last quarter?

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) issued its quarterly earnings results on Friday, April, 24th. The company reported $0.22 EPS for the quarter. The business had revenue of $2.05 billion for the quarter. Chugai Pharmaceutical had a trailing twelve-month return on equity of 22.40% and a net margin of 34.98%.

How do I buy shares of Chugai Pharmaceutical?

Shares of CHGCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 4/24/2026
• Today: 5/06/2026
• Next Earnings (Estimated): 7/24/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:CHGCY
• CIK: 1453934
• Web: www.chugai-pharm.co.jp
• Phone: (133) 281-6611
• Fax: N/A
• Employees: 7,778
• Year Founded: 1925

Profitability

• EPS (Trailing Twelve Months): $0.90
• Trailing P/E Ratio: 29.96
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $2.91 billion
• Net Margins: 34.98%
• Pretax Margin: 47.52%
• Return on Equity: 22.40%
• Return on Assets: 19.08%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.23
• Quick Ratio: 3.56

Sales & Book Value

• Annual Sales: $8.41 billion
• Price / Sales: 10.55
• Cash Flow: $0.97 per share
• Price / Cash Flow: 27.87
• Book Value: $4.12 per share
• Price / Book: 6.54

Miscellaneous

• Outstanding Shares: 3,291,430,000
• Free Float: N/A
• Market Cap: $88.75 billion
• Optionable: Not Optionable
• Beta: 0.63